Cytoreductive Treatment for Essential Thrombocythemia with Peripheral Vascular Disease

Risk Assessment and Classification

• The National Comprehensive Cancer Network recommends classifying patients with prior thrombosis as high-risk, requiring cytoreductive therapy, according to the revised International Prognostic Score of Thrombosis for ET (IPSET-Thrombosis) 2, 3
• Patients with JAK2 V617F mutation have an increased thrombotic risk 3
• Ongoing tobacco use is an additional vascular risk factor 1
• Persistent thrombocytosis is a risk factor for thrombotic events 4

Rationale for Cytoreductive Therapy

• The National Comprehensive Cancer Network recommends cytoreductive therapy for high-risk ET patients to reduce thrombotic complications 2, 5
• Cytoreductive therapy helps normalize platelet counts, reducing thrombotic risk 1, 6
• Normalization of platelet counts may help decrease bleeding risk associated with dual antiplatelet therapy 1, 7

Treatment Recommendations

• The National Comprehensive Cancer Network recommends hydroxyurea as the first-line cytoreductive agent for high-risk ET patients 2
• Target platelet count should be <400 × 10^9/L to reduce thrombotic risk while monitoring for cytopenias 4, 5
• Aspirin and clopidogrel should be continued for secondary prevention of vascular events in patients with a history of peripheral vascular disease with stent placement 1, 6

Monitoring Recommendations

• Regular monitoring of complete blood counts is recommended to assess response to therapy 5
• Monitoring for signs of hydroxyurea intolerance or resistance is necessary 4
• Assessing for bleeding complications, especially in patients on dual antiplatelet therapy, is crucial 6, 7
• Addressing modifiable risk factors, such as smoking cessation, is important 1

Special Considerations

• The combination of thrombocytosis and dual antiplatelet therapy increases bleeding risk 1, 6
• Normalization of platelet counts may help mitigate this bleeding risk 7
• Ongoing tobacco use significantly increases thrombotic risk and should be addressed 1
• Multidisciplinary management with the vascular team is recommended to optimize antiplatelet/anticoagulant strategy 6